Skip to main content

Table 3 Frequency of bleeds in PS-matched patients with and without inhibitors in the CHESS studya

From: Inhibitor clinical burden of disease: a comparative analysis of the CHESS data

Outcomes Patients who never developed inhibitors Patients with current inhibitors p-valueb
N = 58 N = 58
Bleeds in the past 12 months (major and minor bleeds)
  Mean ± SD 3.72 ± 3.95 8.29 ± 9.18 <.0001
  Median (range) 3 (0.00–18.00) 6 (1.00–60.00)  
 Major bleeds, N (%)
  Yes 22 (37.9) 47 (81.0) <.0001
  No 36 (62.1) 11 (19.0)  
 Minor bleeds, N (%)
  Yes 48 (82.8) 58 (100.0) .0047
  No 10 (17.2) 0 (0.0)  
Joint bleeds in past 12 months
  Mean ± SD 0.98 ± 1.15 2.17 ± 1.90 <.0001
  Median (range) 1 (0.00–4.00) 2 (0.00–8.00)  
  Yes, N (%) 32 (55.2) 54 (93.1) <.0001
  No, N (%) 26 (44.8) 4 (6.9)  
  1. BMI body mass index, CHESS Cost of Haemophilia across Europe – a Socioeconomic Survey, PS propensity score, SD standard deviation
  2. aPatients with current inhibitors were matched to patients who had never developed an inhibitor based on demographics (age, BMI, race) and comorbidity status using propensity scores stratified by hemophilia type. Matching was performed using a preset caliper size of 0.035 to maintain the maximum sample size using the smallest caliper width
  3. bP-values were derived from a paired t-test or Wilcoxon signed rank test for continuous post-match variables and the McNemar’s test or exact McNemar’s test for categorical variables; p < .05 indicates statistical significance. The McNemar’s test was not conducted for minor bleeds due to occurrence of event in 100% of inhibitor cohort